top of page


Investing in healthcare data startups that

enhance cancer care and research.

Anchor 1

Cancer care is a fragmented industry, ripe with inefficient care delivery, perverse incentives amongst key stakeholders, regulatory hurdles, and a complex, high-cost patient population. There is a growing dichotomy that exists in cancer care in the U.S. between the availability of clinically sound treatment options and the actual delivery of that care. 

Oncology Ventures will invest in cancer-focused data, infrastructure, IT and services start-ups as we look to fundamentally change the way cancer care is designed and delivered at scale. Note that our fund will not be investing in drugs, therapeutics or medical devices. 


We believe that due to the inherent complexity of oncology and the significant variability that exists amongst cancer cases, even between patients with the same cancer diagnosis, cancer startups deserve a cancer-focused venture fund to help them scale.


Cancer spend in the US is $210B, growing at 12% per year

Rectangle 56.png

Cancer is the 
second-leading cause 
of death in the U.S.


of cancer patients lose
their life savings within
two years of diagnosis


new cancer diagnoses each year


Anchor 2

By leveraging a thesis-based approach within oncology, Oncology Ventures will thoughtfully invest across the cancer care continuum. 

Our investment themes tackle the core issues in cancer care today, focusing on the parts of the journey with the largest costs and greatest potential opportunity to positively impact care outcomes. We will continue to publish our theses publicly. Three overarching themes are...




Infrastructure, Education and Access

Data Accessibility and Scalability

Scalable Care, Navigation and Support

The opportunity for cost savings 
from early cancer detection and 
diagnosis is $26B per year

Only half of cancer patients are treated in accordance with evidence-based medicine

1/3 of hospitalizations are preventable during cancer treatment



Xavier Avat-10130.jpg

Xavier Avat

Chief Business Officer

Moffitt Cancer Center


Xavier Avat is responsible for leading the cancer center’s business development, entrepreneurship, and innovation strategies.

Prior to joining Moffitt, Avat spent nearly 30 years in marketing, operations, and business development, most recently serving as Chief Business Officer at Capricor Therapeutics, a biotech company. Prior to that he served in various leadership roles at several life sciences and biotech companies, including Genentech and Gilead Sciences.


Dr. David Cohn

Interim Chief Executive Officer and Chief Medical Officer

Arthur G. James Cancer Hospital and Solove Research Institute, Ohio State University


Dr. David Cohn is responsible for the strategic direction of the cancer hospital and its clinical practice, where he is a gynecologic oncologist. He is an NCI-funded scientist and holds patents for his discoveries.


He has published over 300 peer-reviewed manuscripts and has held leadership positions in his profession and is editor-in-chief of a premier subspecialty journal.


Douglas Hayes

Executive Director, Venture Studio & Innovation

Atlantic Health System


Douglas Hayes is the Executive Director of Atlantic Health Venture Studio, where he spearheads strategic investments and innovations to enhance healthcare services and outcomes.


Dr. Harlan Levine

President of Health Innovation and Policy

City of Hope


Dr. Harlan Levine is accountable for innovation, product development, and government relations at City of Hope. He previously held executive roles at UnitedHealth Group, Towers Watson, and Anthem Inc.


He currently serves on advisory boards for numerous healthcare organizations and serves as chairman of the board for AccessHope, a spinout company from City of Hope.


Dr. Louis Potters

Chair of Radiation Medicine and Deputy Physician-in-Chief

Northwell Health Cancer Institute


Dr. Louis Potters has published 200+ articles and authored national cancer treatment guidelines. He is currently the Marilyn and Barry Rubenstein Chair in Cancer Research at the Northwell Heath Cancer Institute.


Dr. Nini Wu

Chief Medical and Development Officer of the Navista™ Network

Cardinal Health


We look forward to working with Cardinal Health as they launch Navista™ Network and continue supporting the delivery of patient-centric and value-based care in community oncology.

Prior, Dr. Nini Wu was the Senior VP of Strategic Initiatives at McKesson and President of NY Oncology Hematology.

bottom of page